Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Astrazeneca Plc (AZN)

Astrazeneca Plc (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 323,627,968
  • Shares Outstanding, K 1,550,908
  • Annual Sales, $ 58,739 M
  • Annual Income, $ 10,225 M
  • EBIT $ 13,743 M
  • EBITDA $ 19,476 M
  • 60-Month Beta 0.34
  • Price/Sales 5.53
  • Price/Cash Flow 16.20
  • Price/Book 6.67

Options Overview Details

View History
  • Implied Volatility 26.77% (+0.57%)
  • Historical Volatility 31.74%
  • IV Percentile 67%
  • IV Rank 26.04%
  • IV High 47.30% on 04/08/25
  • IV Low 19.54% on 08/14/25
  • Expected Move (DTE 29) 10.53 (5.05%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 167,394
  • Volume Avg (30-Day) 10,789
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 105,670
  • Open Int (30-Day) 93,288
  • Expected Range 198.09 to 219.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 2.44
  • Number of Estimates 4
  • High Estimate 2.51
  • Low Estimate 2.34
  • Prior Year 2.48
  • Growth Rate Est. (year over year) -1.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
178.08 +17.15%
on 01/21/26
212.71 -1.92%
on 02/18/26
+19.84 (+10.51%)
since 01/16/26
3-Month
176.82 +17.98%
on 11/20/25
212.71 -1.92%
on 02/18/26
+30.64 (+17.22%)
since 11/19/25
52-Week
122.48 +70.33%
on 04/09/25
212.71 -1.92%
on 02/18/26
+61.00 (+41.32%)
since 02/19/25

Most Recent Stories

More News
Forget the Endless AI Stock Debate: This Outperforming Sector is the One to Watch Now

Our top chart strategist explains what investors are missing amid all the chatter over software stocks and AI spending; plus, his favorite stock to trade right now.

AA : 59.69 (-0.86%)
GOOG : 303.56 (-0.13%)
GOOGL : 302.85 (-0.16%)
AZN : 208.62 (-0.02%)
INTC : 44.62 (-1.85%)
IGV : 81.78 (-0.27%)
^BTCUSD : 67,365.84 (+0.67%)
MWH : 30.50 (-0.91%)
Why Wedbush Thinks Norway Could Be Key for This Quantum Computing Stock -- and the Entire Industry

Norway's sovereign wealth fund invested $200 million in IonQ, $39 million in Rigetti, and $4 million in D-Wave. Wedbush sees this as a potential turning point for institutional investment in quantum computing...

MSFT : 398.46 (-0.29%)
GOOG : 303.56 (-0.13%)
GOOGL : 302.85 (-0.16%)
QBTS : 19.38 (+1.63%)
SKYT : 28.83 (+0.31%)
AZN : 208.62 (-0.02%)
IONQ : 33.43 (+0.27%)
RGTI : 16.60 (+2.60%)
AMZN : 204.86 (+0.03%)
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine

Full results from the positive Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine showed AstraZeneca’s BREZTRI Aerosphere (budesonide/glycopyrronium/formoterol...

AZN : 208.62 (-0.02%)
AZN.LN : 15,289.998 (-1.62%)
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH

With after-tax profits surging by close to 50% year-over-year, AstraZeneca emerges as a potential winner among healthcare names reporting earnings this month.

ZBH : 99.25 (+1.02%)
EW : 78.92 (-0.08%)
AZN : 208.62 (-0.02%)
AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US

US ACT on Health Equity contributions support AstraZeneca’s long-term ambition in health equity and total more than $18 million to date

AZN : 208.62 (-0.02%)
AZN.LN : 15,289.998 (-1.62%)
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END

HELP : 6.90 (-2.82%)
AZN : 208.62 (-0.02%)
JNJ : 246.91 (+0.78%)
HELP.NE : 9.5000 (-2.56%)
ABBV : 224.35 (-1.91%)
TAK : 18.66 (+0.65%)
AstraZeneca results: FY and Q4 2025

Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period

AZN : 208.62 (-0.02%)
AZN.LN : 15,289.998 (-1.62%)
Is This the End of the Road for Google Stock? Plus, QQQ’s 100-Day Moving Average Break

Find out what’s on the desk of our top chart expert ahead of Friday’s livestream, including a new red flag on Google stock, a big breakout in BALL, and key ETF updates.

QQQ : 603.47 (-0.38%)
GOOG : 303.56 (-0.13%)
GOOGL : 302.85 (-0.16%)
NVDA : 187.90 (-0.04%)
BALL : 66.03 (-0.42%)
FSLR : 233.30 (-2.21%)
AZN : 208.62 (-0.02%)
MMM : 165.05 (+0.54%)
Bullish Price Surprise: GameStop’s Ryan Cohen Is No Warren Buffett

Michael Burry made a fortune betting against the U.S. housing market. He believes GameStop CEO Ryan Cohen is a Warren Buffett in waiting. Here are three reasons why that’s not the case and why bullish...

AAPL : 260.58 (-1.43%)
COST : 987.82 (-0.83%)
AZN : 208.62 (-0.02%)
WFC : 87.57 (-1.12%)
BRK.B : 496.94 (-0.43%)
KR : 67.63 (-1.79%)
CHWY : 25.86 (+6.99%)
GME : 23.90 (+0.13%)
DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy

Based on results from TROPION-Breast02, showing AstraZeneca and Daiichi Sankyo’s DATROWAY significantly improved overall survival vs. chemotherapy in this patient population ...

AZN : 208.62 (-0.02%)
AZN.LN : 15,289.998 (-1.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 213.04
2nd Resistance Point 211.00
1st Resistance Point 209.81
Last Price 208.62
1st Support Level 206.57
2nd Support Level 204.53
3rd Support Level 203.34

See More

52-Week High 212.71
Last Price 208.62
Fibonacci 61.8% 178.24
Fibonacci 50% 167.60
Fibonacci 38.2% 156.95
52-Week Low 122.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar